HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...
it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer of the thyroid. Six months ago, the Pharmacovigilance Risk ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
First for Women on MSN19h
Amy Schumer Quit Ozempic After 30-Lb. Weight Loss: ‘I Was Shriveling Away'Amy Schumer is getting candid about her unpleasant experience on the weight loss drug Ozempic. The comedian and actress, 43, ...
Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...
Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.
Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback